We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quotient Clinical Announces Major Expansion of its GMP Manufacturing and Formulation Development Capacity
Product News

Quotient Clinical Announces Major Expansion of its GMP Manufacturing and Formulation Development Capacity

Quotient Clinical Announces Major Expansion of its GMP Manufacturing and Formulation Development Capacity
Product News

Quotient Clinical Announces Major Expansion of its GMP Manufacturing and Formulation Development Capacity


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Quotient Clinical Announces Major Expansion of its GMP Manufacturing and Formulation Development Capacity"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Quotient Clinical announces the completion of a major expansion of its Pharmaceutical Sciences facilities in Nottingham, UK.  The GMP (Good Manufacturing Practice) manufacturing suite has doubled in size and now incorporates six independent manufacturing rooms supporting oral, inhaled and parenteral drug products. The formulation development and pharmaceutical analysis laboratory areas have also been significantly increased and now occupy an 11,000ft2 purpose-built facility.

The expansion is in response to the increasing demand for Quotient’s RapidFACT™ (Rapid Formulation development And Clinical Testing) service. RapidFACT enables the efficient investigation and optimisation of new drug product formulations in humans. Conventional development timelines are reduced by 50-60% and API consumption is reduced by up to 90%, delivering significant reductions in associated costs. RapidFACT is particularly effective in addressing the clinical problems associated with poorly soluble drugs or identifying optimal exposure profiles from modified release formulations.

Mark Egerton, MD Quotient Clinical, commented:  “Following the recent announcement of our collaboration agreement with Bend Research, the completion of our Pharmaceutical Sciences laboratory and GMP expansion is a milestone achievement, representing a further significant investment in our RapidFACT service.  The extended capabilities and capacity will be invaluable in underpinning RapidFACT and cementing its position as a key tool in the early drug development process.”

Advertisement